Nivalis Therapeutics, Inc. (Nasdaq: NVLS) announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE